Retrospective cohort study of novel oral agents lenalidomide and duvelisib for relapsed or refractory mycosis fungoides and Sézary syndrome.
Saved in:
| Title: | Retrospective cohort study of novel oral agents lenalidomide and duvelisib for relapsed or refractory mycosis fungoides and Sézary syndrome. |
|---|---|
| Authors: | Elghawy O; Lymphoma Program, Abramson Cancer Center, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania., Yang AG; Lymphoma Program, Abramson Cancer Center, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania., Sussman JH; Lymphoma Program, Abramson Cancer Center, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania., Thomas CJ; Lymphoma Program, Abramson Cancer Center, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania., Carter JS; Lymphoma Program, Abramson Cancer Center, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania., Landsburg DJ; Lymphoma Program, Abramson Cancer Center, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania., Svoboda J; Lymphoma Program, Abramson Cancer Center, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania., Kim E; Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Rook AH; Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Chung J; Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Villasenor-Park J; Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Plastaras JP; Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania., LaRiviere M; Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania., Hubbeling H; Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania., Chelius M; Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania., Nasta SD; Lymphoma Program, Abramson Cancer Center, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania., Chong EA; Lymphoma Program, Abramson Cancer Center, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania., Schuster SJ; Lymphoma Program, Abramson Cancer Center, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania., Barta SK; Lymphoma Program, Abramson Cancer Center, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: stefan.barta@pennmedicine.upenn.edu. |
| Source: | Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2025 Mar; Vol. 92 (3), pp. 634-636. Date of Electronic Publication: 2024 Nov 16. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Mosby Country of Publication: United States NLM ID: 7907132 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-6787 (Electronic) Linking ISSN: 01909622 NLM ISO Abbreviation: J Am Acad Dermatol Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
